Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-19 patients: A multicenter retrospective study

Background High incidence of asymptomatic venous thromboembolism (VTE) has been observed in severe COVID-19 patients, but the characteristics of symptomatic VTE in general COVID-19 patients have not been described. Objectives To comprehensively explore the prevalence and reliable risk prediction for VTE in COVID-19 patients. Methods/Results This retrospective study enrolled all COVID-19 patients with a subsequent VTE in 16 centers in China from January 1 to March 31, 2020. A total of 2779 patients were confirmed with COVID-19. In comparison to 23,434 non-COVID-19 medical inpatients, the odds ratios (ORs) for developing symptomatic VTE in severe and non-severe hospitalized COVID-19 patients were 5.94 (95% confidence interval [CI] 3.91-10.09) and 2.79 (95% CI 1.43-5.60), respectively. When 104 VTE cases and 208 non-VTE cases were compared, pulmonary embolism cases had a higher rate for in-hospital death (OR 6.74, 95% CI 2.18-20.81). VTE developed at a median of 21 days (interquartile range 13.25-31) since onset. Independent factors for VTE were advancing age, cancer, longer interval from symptom onset to admission, lower fibrinogen and higher D-dimer on admission, and D-dimer increment (DI) >= 1.5-fold; of these, DI >= 1.5-fold had the most significant association (OR 14.18, 95% CI 6.25-32.18, p = 2.23 x 10(-10)). A novel model consisting of three simple coagulation variables (fibrinogen and D-dimer levels on admission, and DI >= 1.5-fold) showed good prediction for symptomatic VTE (area under the curve 0.865, 95% CI 0.822-0.907, sensitivity 0.930, specificity 0.710). Conclusions There is an excess risk of VTE in hospitalized COVID-19 patients. This novel model can aid early identification of patients who are at high risk for VTE.

Automated summary

The study found that severe and non-severe hospitalized COVID-19 patients have nearly 6 times and 3 times higher odds of developing symptomatic VTE compared to general medical inpatients. VTE commonly develops at a median of 21 days after symptom onset and independent risk factors include advancing age, cancer, longer interval from symptom onset to admission, lower fibrinogen, and higher D-dimer levels.